Overexpression of a Modified Human Malonyl-CoA Decarboxylase Blocks the Glucose-induced Increase in Malonyl-CoA Level but Has No Impact on Insulin Secretion in INS-1-derived (832/13) beta -Cells*

Hindrik MulderDagger §, Danhong LuDagger §, John Finley IV||, Jie AnDagger §, Jonathan Cohen§**, Peter A. AntinozziDagger , J. Denis McGarryDagger §, and Christopher B. NewgardDagger §DaggerDagger

From the Touchstone Center for Diabetes Research and Departments of Dagger  Biochemistry, § Internal Medicine, and ** Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas 75390 and the || Department of Biochemistry and Medicine, Dartmouth Medical School, Hanover, New Hampshire 03755

Received for publication, November 15, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The long-chain acyl-CoA (LC-CoA) model of glucose-stimulated insulin secretion (GSIS) holds that secretion is linked to a glucose-induced increase in malonyl-CoA level and accumulation of LC-CoA in the cytosol. We have previously tested the validity of this proposal by overexpressing goose malonyl-CoA decarboxylase (MCD) in INS-1 cells, but these studies have been criticized due to: 1) the small insulin secretion response (2-4-fold) of the INS-1 cells used; 2) unknown contribution of the ATP-sensitive K+ (KATP) channel-independent pathway of GSIS in INS-1 cells, which has been implicated as the site at which lipids regulate insulin granule exocytosis; and 3) deletion of the N-terminal mitochondrial targeting sequence, but not the C-terminal peroxisomal targeting sequence in the goose MCD construct, raising the possibility that a significant fraction of the overexpressed enzyme was localized to peroxisomes. To address these outstanding concerns, INS-1-derived 832/13 cells, which exhibit robust KATP channel-dependent and -independent pathways of GSIS, were treated with a new adenovirus encoding human MCD lacking both its mitochondrial and peroxisomal targeting sequences (AdCMV-MCDDelta 5), resulting in large increases in cytosolic MCD activity. Treatment of 832/13 cells with AdCMV-MCDDelta 5 completely blocked the glucose-induced rise in malonyl-CoA and attenuated the inhibitory effect of glucose on fatty acid oxidation. However, MCD overexpression had no effect on KATP channel-dependent or -independent GSIS in 832/13 cells. Furthermore, combined treatment of 832/13 cells with AdCMV-MCDDelta 5 and triacsin C, an inhibitor of long chain acyl-CoA synthetase that reduces LC-CoA levels, did not impair GSIS. These findings extend our previous observations and are not consistent with the LC-CoA hypothesis as originally set forth.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The regulation of insulin secretion by glucose is mediated by metabolism of the sugar in pancreatic islet beta -cells, resulting in an increase in the ATP:ADP ratio and closure of ATP-dependent K+ (KATP)1 channels. Subsequently, voltage-gated Ca2+ channels open, intracellular Ca2+ rises, and insulin exocytosis is initiated (1). However, it has become clear that this is a minimal model of glucose sensing, because glucose-stimulated insulin secretion (GSIS) still occurs when closure of the KATP channel or the rise in intracellular Ca2+ are prevented (2, 3). It has been suggested that factors that complement changes in ATP:ADP ratios in regulation of insulin secretion may arise from post-mitochondrial metabolism of glucose, and interaction of glucose and lipid metabolism. The long-chain acyl-CoA (LC-CoA) model of GSIS holds that malonyl-CoA levels increase in response to increasing glucose concentrations, resulting in inhibition of carnitine palmitoyltransferase I and fatty acid oxidation (4-6). This could lead to accumulation of LC-CoA in the cytosol, which may act as a coupling factor in stimulation of insulin secretion (7).

Our laboratory has recently addressed the LC-CoA model using adenovirus-mediated overexpression of goose malonyl-CoA decarboxylase (MCD) in INS-1 cells (8). In these studies, we were able to partially block the glucose-induced increase in malonyl-CoA levels and lessen glucose-mediated inhibition of fatty acid oxidation. Despite this perturbation of the link between glucose and lipid metabolism, GSIS remained unchanged. However, the findings and conclusions of this paper have been called into question at several levels (9, 10). Concerns raised include: 1) the INS-1 cell line used in our studies exhibited only a 2-4-fold stimulation of insulin secretion as glucose was raised from 3 to 15 mM, as opposed to freshly isolated rat islets, which can exhibit a 10-15-fold response. 2) It is unclear if the so-called KATP channel-independent pathway of GSIS is operative in INS-1 cells. This pathway, which is revealed when beta -cells are exposed to depolarizing K+, has been implicated as the site at which lipids regulate insulin granule exocytosis (10, 11). 3) The goose MCD cDNA used in our previous study had its N-terminal mitochondrial targeting sequence deleted, but contained an intact C-terminal SKL peroxisomal targeting motif, raising the possibility that a significant fraction of the overexpressed enzyme failed to localize to the cytosol.

The current study was undertaken to address these outstanding concerns. This has been facilitated by our recent development of INS-1-derived cell lines (e.g. 832/13) with robust KATP-channel-dependent and -independent GSIS (12). Under normal ionic conditions, 832/13 cells exhibit a 10-fold increase in insulin secretion when glucose is raised from 3 to 15 mM, and are also responsive to glucose when the KATP channel is by-passed by application of depolarizing K+ and diazoxide. Thus, these cells appear to be an improved model for evaluation of secretory mechanisms relative to parental INS-1 cells, which comprised a mixture of glucose-responsive and -unresponsive cells (12). In addition, since publication of our prior study, the human MCD cDNA has been cloned (13), and mutant forms of the cDNA lacking the mitochondrial and peroxisomal localization sequences have been inserted into adenovirus vectors. With this cadre of improved reagents, we have re-examined the effect of MCD overexpression on GSIS, and find no impairment of robust GSIS in 832/13 cells, despite complete blockade of the glucose-induced rise in malonyl-CoA level. These findings extend our previous observations (8) and are not consistent with the LC-CoA hypothesis as originally set forth.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

All materials were from Sigma, unless otherwise stated.

Cell Culture-- The INS-1-derived cell line 832/13 was used throughout this study (12). These cells were cultured in RPMI 1640 with 11.1 mM D-glucose, supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES, 2 mM glutamine, 1 mM sodium pyruvate, and 50 µM beta -mercaptoethanol, at 37 °C in a humidified atmosphere containing 5% CO2.

Preparation and Use of Recombinant Adenoviruses-- Fragments of the cDNA encoding human MCD lacking the mitochondrial localization sequence (amino acids 1-39) or the mitochondrial and peroxisomal localization sequences (amino acids 1-39 and 490-493; see Ref. 13 for complete sequence of human MCD) were cloned into the adenovirus vector pACCMV.pLpA (14) and used to prepare recombinant adenoviruses (AdCMV-MCD6 and AdCMV-MCDDelta 5, respectively) as described previously (15). The resulting viruses were plaque-purified (15) and used to treat confluent 832/13 cells at varying titers as described in the figure legends. A virus containing the bacterial beta -galactosidase gene (AdCMV-beta GAL) was used as a control (16). After a 1-h incubation with viruses, cells were washed once in phosphate-buffered saline, culture medium was added, and assays and analyses were undertaken 24 h later.

Malonyl-CoA Decarboxylase Activity Assay-- MCD activity was determined as the rate of decarboxylation of malonyl-CoA to acetyl-CoA as previously described (8). In brief, the rate of acetyl-CoA formation was monitored by cleavage of its thioester bond by carnitine acetyltransferase. The thiol group of CoA was colorimetrically measured at 412 nm over 5-10 min, a time period over which the rate of product accumulation was linear. Activity was measured either in crude cell extracts or in cytosol-enriched fractions. Crude extracts were prepared by collection of cells in 50 mM HEPES buffer, pH 7.2, containing protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 50 mM benzamidine, and 50 µg/ml trypsin inhibitor), and homogenization by 10 strokes in a Dounce homogenizer. A portion of these extracts was used to prepare cytosol-enriched fractions by centrifugation at 12,000 rpm for 20 min, transfer of the supernatant into a new tube, and further centrifugation at 100,000 × g for 20 min. The resultant supernatant was collected for assay of MCD activity, and values were normalized to total protein.

Malonyl-CoA Assay-- 832/13 cells were cultured in RPMI containing 3 mM glucose for 24 h following viral treatment. Cells were washed with HEPES-balanced salt solution (HBSS: 114 mM NaCl, 4.7 mmol KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 25.5 mM NaHCO3, pH 7.2) containing 3 mM glucose and incubated in the same buffer for 2 h. Following this preincubation, cells were switched to HBSS containing 3 or 15 mM glucose for 30 min. Cells were collected into 2-ml isopropylene tubes by adding 1.5 ml of ice-cold 3.5% (v/v) HClO4 to each plate and centrifugation of the collected extract at 12,000 rpm for 5 min at 4 °C. The supernatant containing acid-soluble metabolites was neutralized to pH 2-3 with 5 N KOH and to pH 6 with 2.5 M KHCO3. After centrifugation at 2000 rpm for 5 min, the supernatant volume was measured, prior to its transfer to a 15-ml tube. For assay, each sample was divided into two 0.2-ml aliquots. 50 pmol of malonyl-CoA was added to one of the two samples, and malonyl-CoA levels were assayed in both samples according to the method of McGarry et al. (17), using purified fatty acid synthase.

[1-14C]Palmitate Oxidation-- 832/13 cells in 6-well plates were harvested by light trypsinization and kept in HBSS containing 3 mM glucose for 30 min at 37 °C. The cells were contained in center wells (Kontes, Vineland, NJ) suspended from a rubber sleeve stopper (Fisher, Pittsburgh, PA) inserted into a glass scintillation vial. A reaction mixture consisting of 0.5 mM palmitic acid complexed to 1% bovine serum albumin (essentially fatty acid free), with ~1 × 107 cpm/µmol [1-14C]-palmitic acid (PerkinElmer Life Sciences, Boston, MA) as tracer, 0.8 mM L-carnitine, and glucose, at a final concentration of 3 or 15 mM, was added and the vials sealed. After 2 h the reaction was terminated by injection of 100 µl of 7% perchloric acid into the center well. The rate of [1-14C]palmitate oxidation was measured as released 14CO2, which was trapped by adding 300 µl of benzethonium hydroxide to the bottom of the sealed vials, followed by an additional 2-h incubation at 37 °C. Then, the center wells and rubber stoppers were discarded, scintillation mixture was added, and 14CO2 counted.

Insulin Secretion Studies-- For assay of insulin secretion, 832/13 cells were grown to confluence in 12-well plates and treated with the various recombinant adenoviruses. After 24 h, cells were washed in HBSS with 0.2% bovine serum albumin and 3 mM D-glucose followed by preincubation in 3 ml of the same buffer for 2 h. Insulin secretion was then measured by static incubation of the cells for 2 h in 1.5 ml of HBSS containing glucose, triacsin C, and oleate/palmitate (2:1 molar ratio) concentrations indicated in figure legends. When ATP-sensitive K+ channel-independent GSIS was examined, the K+ concentration in the HBSS during the static incubation was increased to 35 mM, while the Na+ concentration was lowered to 89.8 mM, and 250 µM diazoxide was added. Because the human proinsulin gene is stably expressed in the 832/13 cell line (12), insulin was measured using the Coat-a-Count kit (DPC, Los Angeles, CA). The antibody in this assay recognizes human insulin and cross-reacts ~20% with rat insulin.

Statistical Analysis-- Data represent mean ± S.E. and different experimental groups were compared either with a one-tailed Student's t test or a one-way ANOVA followed by Newman-Keul's test for comparisons post-hoc. A probability level of p < 0.05 was considered to be statistically significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

MCD Activities of the Different Recombinant Adenoviruses in 832/13 Cells-- In our previous work, a recombinant adenovirus containing the cDNA encoding malonyl-CoA decarboxylase from the goose uropygial gland (AdCMV-MCDgoose) was used to partially attenuate increases in malonyl-CoA levels during glucose stimulation of INS-1 cells (8). The cDNA used in this virus encoded a protein that lacked its N-terminal mitochondrial, but not the C-terminal peroxisomal localization sequence. These features, coupled with its non-mammalian origin, may have limited the ability of the modified goose MCD to degrade malonyl-CoA formed in the cytosol of rat cells, which is the critical pool for modulation of carnitine palmitoyltransferase I enzyme activity. To deal with this concern, we have constructed three new adenoviruses containing modified human MCD cDNAs. The first of these is analagous to the goose MCD construct in that it lacks its N-terminal mitochondrial localization sequence (AdCMV-MCD6), and the second lacks both the mitochondrial and SKL targeting sequences (AdCMV-MCDDelta 5). Finally, a control virus was constructed containing the MCD cDNA of a patient with two point mutations in the coding sequence that render the enzyme catalytically inactive (AdCMV-MCDmut) (13).

To assess the capacity of the different recombinant adenoviruses to increase MCD activity, 832/13 cells were treated with increasing doses of the viruses. Twenty-four h after viral treatment, total MCD activity was determined in unfractionated cell extracts. As is shown in Fig. 1, each of the viruses encoding functional enzymes (AdCMV-MCDgoose, AdCMV-MCD6, or AdCMV-MCDDelta 5) increased enzyme activity in a dose-dependent manner, with maximal values ~20-fold higher than in either of the control groups (AdCMV-beta GAL-treated or AdCMV-MCDmut-treated cells). Interestingly, the maximal MCD activity achieved was 10-fold higher in this study than in our previous report (8). The reasons for this increased efficiency of expression of MCD in the current study are not known, but could relate to the fact that we treated the cells with a higher viral titer over a shorter time period than in our previous study. Alternatively, expression of the construct may have been more efficient in the novel 832/13 cells than in the parental INS-1 cells used previously (8).



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Titering of adenoviruses expressing MCD. 832/13 cells were treated with the indicated multiplicities of infection (MOI) of various recombinant adenoviruses, abbreviated as described under "Materials and Methods." MCD enzymatic activity was measured in total cell extracts 24 h after viral treatment. Results are mean ± S.E. of three independent experiments performed in duplicate.

More relevant than total MCD activity in whole cell extracts is the amount of activity residing in the cytosolic compartment of cells. To estimate this, different batches of 832/13 cells were treated with the same titers of AdCMV-MCDgoose, AdCMV-MCD6, or AdCMV-MCDDelta 5 adenoviruses, and used for preparation of cytosolic cell fractions 24 h after viral treatment. Fig. 2 shows that the MCD activity in the cytosolic fraction of AdCMV-MCDDelta 5 was increased by 120 and 50% compared with cells treated with AdCMV-MCDgoose or AdCMV-MCD6, respectively. Thus, while the three MCD viruses caused similar increases in MCD activity in whole cell extracts, AdCMV-MCDDelta 5 containing the cDNA that lacks both its mitochondrial and peroxisomal localization sequences caused a larger increase in cytosolic activity than the other two constructs. In theory, AdCMV-MCDDelta 5 may therefore be a more specific tool for perturbing the link between metabolism of glucose and lipids, because the pool of malonyl-CoA that is implicated in beta -cell stimulus-secretion coupling is formed in the cytosol (9).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Cytoplasmic MCD activities in MCD-overexpressing 832/13 cells. 832/13 cells were treated with the indicated recombinant adenoviruses at an MOI of 25 for each virus. Total cell extracts were prepared, and a portion was used for measurement of MCD enzymatic activity (white bars, left). Cytoplasm-enriched fractions were then prepared with the remaining total cell extract as described under "Materials and Methods," and MCD activity was measured in this fraction (black bars, right). Data represents the mean ± S.E. for three independent experiments; *, p < 0.05, and **, p < 0.01.

Effect of MCD Overexpression on Malonyl-CoA Levels-- In our previous study in which goose MCD was overexpressed in INS-1 cells, cellular malonyl-CoA levels were increased in response to changes in external glucose concentrations, although total malonyl-CoA levels were significantly lower in MCD overexpressing cells than in controls (8). The incomplete blockade in malonyl-CoA formation could have led to an erroneous conclusion about its role in regulation of insulin secretion. We therefore investigated the ability of our new MCD adenoviruses to lower malonyl-CoA levels in 832/13 cells. As shown in Fig. 3, malonyl-CoA levels were increased by 4.8-fold in AdCMV-beta GAL-treated 832/13 cells as glucose was raised from 3 to 15 mM. This glucose-induced rise in malonyl-CoA levels was completely blocked in 832/13 cells treated with any of the three MCD viruses, AdCMV-MCDgoose, AdCMV-MCD6, or AdCMV-MCDDelta 5. The more effective blockade of malonyl-CoA production is consistent with the higher levels of enzyme activity achieved in this study compared with the previous one (8). Given the similar performance of the three viral constructs, all subsequent experiments were carried out exclusively with AdCMV-MCDDelta 5.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Malonyl-CoA levels in MCD-overexpressing 832/13 cells. 832/13 cells were treated with the indicated recombinant adenoviruses (see "Materials and Methods" for description of abbreviations). After viral treatment, cells were cultured in 3 mM glucose for 24 h, at which point cells were washed by HBSS containing 3 mM glucose, and further incubated in the same buffer for 2 h. Cells were then switched to HBSS containing either 3 or 15 mM glucose, and after an additional 30 min, malonyl-CoA was extracted and measured as described under "Materials and Methods." Data represent the mean ± S.E. for three independent measurements. The asterisk symbol (*) indicates that the malonyl-CoA level at 15 mM glucose was significantly higher than at 3 mM glucose in the AdCMV-beta GAL-treated control cells, with p < 0.001

Impact of Recombinant MCD Adenoviruses on Fatty Acid Oxidation in 832/13 Cells-- We next proceeded to evaluate the metabolic effects of the AdCMV-MCDDelta 5 virus. [1-14C]Palmitate oxidation was measured in 832/13 cells treated with a titer of AdCMV-MCDDelta 5 that raised MCD activity to ~1.8 µmol/mg/min. As shown in Fig. 4, incubation of AdCMV-beta GAL-treated 832/13 cells at 15 mM glucose reduced the rate of [1-14C]palmitate oxidation to 31% of that in cells incubated in 3 mM glucose. Thus, glucose regulates fatty acid oxidation in 832/13 cells in a fashion similar to what has been reported for rat islets (18) and INS-1 cells (8). In contrast, the high glucose concentration was much less effective at suppressing fatty acid oxidation in cells treated with AdCMV-MCDDelta 5, such that the rate remained at 63% of that in cells incubated in 3 mM glucose.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   [1-14C]Palmitate oxidation in 832/13 cells. 832/13 cells were treated with AdCMV-MCDDelta 5 or AdCMV-beta GAL. 24 h after viral treatment, [1-14C]palmitate oxidation was measured as described under "Materials and Methods." Results represent the mean ± S.E. of four independent experiments. The double asterisk symbol (**) (p < 0.01) indicates that at 15 mM glucose, cells treated with AdCMV-MCDDelta 5 oxidized fatty acids at a significantly higher rate than cells treated with AdCMV-beta GAL.

There is a possibility that the most pronounced metabolic effects of MCD overexpression occur at higher viral titers than used in the experiment of Fig. 4. Alternatively, high viral titers could have compromised certain aspects of metabolic function, so that the effects on fatty acid oxidation may have been more pronounced at lower viral titers. To address this, we determined the titer dependence of the effect of AdCMV-MCDDelta 5 on fatty acid oxidation. At one-fourth the viral titer used in the foregoing experiments (5 × 105 pfu/well corresponding to an MCD activity of 0.85 µmol/mg/min) the effect of MCD overexpression to impair glucose-mediated inhibition of fatty acid oxidation was already maximal. Moreover, it was neither increased nor decreased when the titer was increased stepwise over a 4-fold range (data not shown). This incomplete reversal of glucose suppression of fatty acid oxidation in AdCMV-MCDDelta 5 expressing cells, despite the complete blockade of glucose-induced malonyl-CoA accumulation, suggests that factors other than the malonyl-CoA level are involved in regulation of fatty acid oxidation by high glucose.

Glucose-stimulated Insulin Secretion in AdCMV-MCDDelta 5-transduced and/or Triacsin-treated 832/13 Cells-- Having established that AdCMV-MCDDelta 5 blocks glucose-induced malonyl-CoA production and attenuates the inhibitory effect of glucose on fatty acid oxidation, we proceeded to evaluate the effects of this new reagent on insulin secretion. In 832/13 cells treated with the control virus AdMV-beta GAL, 15 mM glucose caused a 10-fold increase in insulin secretion relative to secretion at 3 mM glucose (Fig. 5A). Cells treated with AdCMV-MCDDelta 5 exhibited the same robust response to stimulatory glucose, providing clear evidence that a rise in malonyl-CoA and complete blockade of fatty acid oxidation are not required events in GSIS. This lack of effect of MCD was not specific to AdCMV-MCDDelta 5, as cells treated with AdCMV-MCD6 exhibited the same potent response to stimulatory glucose (data not shown).



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   Glucose-stimulated insulin secretion in 832/13 cells. 832/13 cells were treated with the indicated adenoviruses and cultured for 24 h in medium containing 3 mM glucose. Insulin secretion was then measured by incubating cells in HBSS containing either 3 or 15 mM glucose for 2 h. Panel A, experiments conducted in the presence of normal K+ concentrations. Panel B, experiments conducted in the presence of depolarizing K+ (35 mM) and 250 µM diazoxide to measure KATP channel-independent glucose sensing. Results represent the mean ± S.E. for eight independent experiments for panel A and four independent experiments for panel B. Insulin secretion was compared with basal secretion measured at 3 mM glucose for cells treated with each virus, using a one-way ANOVA followed by Newman-Keul's test post-hoc; *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Insulin secretion was also studied in the presence of 35 mM K+ and 250 µM diazoxide, which allows measurement of the KATP channel-independent pathway of glucose sensing (2). It has been suggested that his pathway is responsible for the LC-CoA-mediated potentiation of GSIS (10, 11). However, in the presence of the high K+ concentration and diazoxide, 15 mM glucose had the same stimulatory effect (2.3-fold) on insulin secretion in AdCMV-beta GAL or AdCMV-MCDDelta 5-treated 832/13 cells (Fig. 5B), demonstrating that blockade of malonyl-CoA production has no effect on glucose sensing via the KATP channel-independent pathway.

We have previously demonstrated that treatment of INS-1 cells with triacsin C, an inhibitor of LC-CoA synthetase, results in a 50% decrease in LC-CoA levels, with no effect on GSIS (8). We therefore examined the effects of combined treatment of 832/13 cells with the AdCMV-MCDDelta 5 virus, which blocks malonyl-CoA accumulation, and triacsin C, which lowers LC-CoA levels. The combined addition of AdCMV-MCDDelta 5 and triacsin C to 832/13 cells had no effect on the 10-fold stimulation of insulin secretion by 15 mM glucose under normal culture conditions (Fig. 5A) or on the stimulation by glucose of insulin secretion via the KATP channel-independent pathway (Fig. 5B). Thus, complete blockade of malonyl-CoA accumulation and simultaneous lowering of the cellular LC-CoA pool has no effect on GSIS.

Preincubation of AdCMV-MCDDelta 5-treated 832/13 Cells with Free Fatty Acids-- Finally, we examined the possibility that limited endogenous lipid stores in insulinoma-derived clonal beta -cells could impact our ability to demonstrate a link between glucose and lipid metabolism for regulation of GSIS. To test this possibility, 832/13 cells were preincubated for 48 h in 0.5 mM oleate/palmitate, prior to treatment with AdCMV-MCDDelta 5. GSIS was then assayed after an additional 24 h of culture in 0.5 mM oleate/palmitate. These maneuvers were designed to increase cellular storage of lipids. As seen in Fig. 6, culture of 832/13 for 3 days in 0.5 mM oleate/palmitate resulted in attenuation of GSIS, such that these cells exhibited a 4-fold response to 15 mM glucose, compared with the 10-fold response of cells grown in normal medium. This blunting effect of chronic culture in fatty acids is similar to that previously described in isolated rat and human islets (19, 20). Nevertheless, glucose responsiveness was not different in AdCMV-beta GAL versus AdCMV-MCDDelta 5-treated cells that had been cultured in the presence of 0.5 mM oleate/palmitate. The impact of acute stimulation of 832/13 cells with free fatty acid was also tested in cells cultured both in regular RPMI and in RPMI supplemented with 0.5 mM oleate/palmitate. Again, GSIS was similarly potentiated by 0.5 mM oleate/palmitate in AdCMV-beta GAL and AdCMV-MCDDelta 5-treated cells, regardless of whether they were preincubated with the fatty acid mixture. Thus, neither an increment in cellular lipids nor acute exogenous administration of lipids uncovers a requirement for malonyl-CoA in regulation of insulin secretion.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of preincubation of 832/13 cells in fatty acids. 832/13 cells were treated with either AdCMV-MCDDelta 5 or AdCMV-beta GAL after 48 h of culture in medium lacking (left bars) or containing (right bars) 0.5 mM oleate/palmitate. After viral treatment, medium containing 0.5 mM oleate/palmitate was again added to the cells, and after a further 24 h GSIS was assayed in a 2-h static incubation with or without co-stimulation by 1 mM oleate/palmitate. Results represent mean ± S.E. for five independent experiments for each condition. Insulin secretion was compared with basal secretion measured at 3 mM glucose for cells treated with each virus, using a one-way ANOVA followed by Newman-Keul's test post-hoc. In addition, comparisons between cells stimulated at 15 mM glucose with or without the addition of 1 mM oleate/palmitate are shown as bars; *, p < 0.05; **, p < 0.01; ***, p < 0.001.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The idea that malonyl-CoA could be a coupling factor in beta -cell stimulus-secretion originated from the observation that the levels of this intermediate rise prior to insulin secretion when HIT-T15 hamster insulinoma cells are exposed to glucose (4-6). Furthermore, the glucose-induced rise in malonyl-CoA was coincident with inhibition of fatty acid oxidation and was assumed to result in an increase in cytosolic levels of LC-CoA. That LC-CoA could be an effector molecule in beta -cell stimulus-secretion coupling was further suggested by the fact that perfusion of permeabilized HIT-T15 cells with LC-CoA-esters induced insulin secretion (7). Additional supporting evidence for the LC-CoA model comes from the use of hydroxycitrate, which inhibits ATP-citrate lyase and consequently malonyl-CoA formation. Use of this agent to disrupt the link between glucose and malonyl-CoA formation was shown to inhibit GSIS from the perfused rat pancreas (18). Conversely, inhibition of carnitine palmitoyltransferase I and fatty acid oxidation with agents such as etomoxir-stimulated GSIS from the perfused pancreas (18). Finally, stable expression of an acetyl-CoA carboxylase-antisense construct in INS-1 cells resulted in lowering of malonyl-CoA levels, increased fatty acid oxidation, and inhibition of GSIS (21).

In contrast to these results, we have previously demonstrated that adenovirus-mediated overexpression of goose MCD in INS-1 cells reduced malonyl-CoA levels and partially alleviated inhibition of fatty acid oxidation by glucose (8). Triacsin C, an inhibitor of LC-CoA synthetase was also shown to block glucose incorporation into lipids and lower LC-CoA levels, but neither the molecular nor the pharmacologic approaches to impairing LC-CoA formation had any effect on GSIS (8). The current study has attempted to address perceived limitations of the prior work that have come to light (9, 10), and to resolve the apparent discrepancy between our work and that of others. Key improvements in our experimental approach reported herein include. 1) The use of a new INS-1-derived cell line with robust KATP channel-dependent or -independent pathways of glucose sensing (12). 2) The construction of new recombinant adenoviruses containing the cDNAs encoding human forms of MCD, including one in which both the mitochondrial and peroxisomal localization sequences were removed to enhance expression of the enzyme in the cytosolic compartment. 3) New studies involving preincubation of cells in a mixture of oleate and palmitate to boost cellular lipid stores. 4) Co-application of the molecular (AdCMV-MCDDelta 5) and pharmacologic (triacsin C) reagents to maximally perturb malonyl-CoA and LC-CoA synthesis. These improvements have allowed us to demonstrate in a clear and unequivocal fashion that complete blockade of malonyl-CoA accumulation has no impact on the KATP channel-dependent or independent pathways of GSIS. The co-application of AdCMV-MCDDelta 5 and triacsin C also has no effect on insulin secretion, suggesting that robust glucose sensing is not linked to changes in total LC-CoA levels. Furthermore, preincubation of 832/13 cells for 3 days in 0.5 mM oleate/palmitate impaired glucose sensing, as has been described extensively in islets (19, 20). However, culture of cells in fatty acids does not uncover an effect of AdCMV-MCDDelta 5 on GSIS. Finally, treatment of 832/13 cells with AdCMV-MCDDelta 5 does not affect fatty acid potentiation of GSIS, supporting the view that this action of fatty acids is not related to their oxidation (18).

How can our findings be reconciled with those supporting the malonyl-CoA/LC-CoA model of glucose sensing? First, the rise in malonyl-CoA levels that occurs prior to insulin release is not proof of a causal relationship between the two phenomena. Also, the recently reported effect of palmitoyl-CoA on insulin secretion is modest, and the use of permeabilized cells in these studies raises questions about the physiological relevance of the experiment (7). Moreover, in view of the proposed critical role of mitochondrial metabolism in GSIS (22), abrogation of GSIS conferred by hydroxycitrate may be due in part to perturbed mitochondrial metabolism. It should also be noted that the inhibitory effect of hydroxycitrate on GSIS is not observed in isolated rat islets (23). The enhanced GSIS that accompanies inhibition of fatty acid oxidation by carnitine palmitoyltransferase I inhibitors may be explained by the fact that these compounds, e.g. 2-bromopalmitate or etomoxir, are modified fatty acids, which may act like native lipids to potentiate GSIS independent of their effects on fatty acid oxidation (18). Finally, chronic lowering of malonyl-CoA levels in INS-1 cells with a stable transfection strategy may cause profound alterations in beta -cell metabolism and function (21). Of particular concern here is that chronic lowering of malonyl-CoA levels could result in depletion of stored lipids. It has been shown that depletion of beta -cell lipids in nicotinamide-treated animals or humans (24, 25) or in hyperleptinemic rats (26) blocks insulin secretion in response to glucose and many other secretagogues. Interestingly, in both cases, GSIS is immediately restored by provision of free fatty acids. These findings clearly support an essential role for lipids in regulation of insulin secretion, possibly at the level of membrane lipid turnover or acylation of regulatory proteins. The latter possibility is also supported by recent studies in which insulin secretion was inhibited by addition of cerulenin, an inhibitor of protein acylation (11). However, while a minimal pool of lipids may be essential for normal regulation of insulin secretion, the current study provides strong evidence that glucose sensing can occur in the absence of a rise in malonyl-CoA and despite acute perturbation of lipid metabolism.


    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants DK-42582 (to C. B. N.) and DK-18573 (to J. D. M) and a grant from the Reynold's Foundation (to C. B. N. and J. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Recipient of a Postdoctoral Fellowship from the Juvenile Diabetes Foundation International.

Dagger Dagger To whom correspondence should be addressed: Touchstone Center for Diabetes Research, Rm. Y8.212, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390. Fax: 214-648-9191; E-mail: newgard@utsw.swmed.edu.

Published, JBC Papers in Press, December 11, 2000, DOI 10.1074/jbc.M010364200


    ABBREVIATIONS

The abbreviations used are: KATP, ATP-sensitive K+; GSIS, glucose-stimulated insulin secretion; LC-CoA, long-chain acyl-CoA; MCD, malonyl-CoA decarboxylase; HBSS, Hepes balanced salt solution.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Newgard, C. B., and McGarry, J. D. (1995) Annu. Rev. Biochem. 64, 689-719[CrossRef][Medline] [Order article via Infotrieve]
2. Gembal, M., Gilon, P., and Henquin, J. C. (1992) J. Clin. Invest. 89, 1288-1295[Medline] [Order article via Infotrieve]
3. Komatsu, M., Schermerhorn, T., Aizawa, T., and Sharp, G. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10728-10732[Abstract]
4. Corkey, B. E., Glennon, M. C., Chen, K. S., Deeney, J. T., Matschinsky, F. M., and Prentki, M. (1989) J. Biol. Chem. 264, 21608-21612[Abstract/Free Full Text]
5. Prentki, M., Vischer, S., Glennon, M., Regazzi, R., Deeney, J., and Corkey, B. E. (1992) J. Biol. Chem. 267, 5802-5810[Abstract/Free Full Text]
6. Prentki, M., and Corkey, B. E. (1996) Diabetes 45, 273-283[Abstract]
7. Deeney, J. T., Gromada, J., Hoy, M., Olsen, H. L., Rhodes, C. J., Prentki, M., Berggren, P. O., and Corkey, B. E. (2000) J. Biol. Chem. 275, 9363-9368[Abstract/Free Full Text]
8. Antinozzi, P. A., Segall, L., Prentki, M., McGarry, J. D., and Newgard, C. B. (1998) J. Biol. Chem. 273, 16146-16154[Abstract/Free Full Text]
9. Corkey, B. E., Deeney, J. T., Yaney, G. C., Tornheim, K., and Prentki, M. (2000) J. Nutr. 130 Suppl. 2S, 299S-304S[Medline] [Order article via Infotrieve]
10. Komatsu, M., Yajima, H., Yamada, S., Kaneko, T., Sato, Y., Yamauchi, K., Hashizume, K., and Aizawa, T. (1999) Diabetes 48, 1543-1549[Abstract]
11. Yajima, H., Komatsu, M., Yamada, S., Straub, S. G., Kaneko, T., Sato, Y., Yamauchi, K., Hashizume, K., Sharp, G. W. G., and Aizawa, T. (2000) Diabetes 49, 712-717[Abstract]
12. Hohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., and Newgard, C. B. (2000) Diabetes 49, 424-430[Abstract]
13. Gao, J., Waber, L., Bennett, M. J., Gibson, K. M., and Cohen, J. C. (1999) J. Lipid Res. 40, 178-182[Abstract/Free Full Text]
14. Gomez-Foix, A. M., Coats, W. S., Baque, S., Alam, T., Gerard, R. D., and Newgard, C. B. (1992) J. Biol. Chem. 267, 25129-25134[Abstract/Free Full Text]
15. Becker, T. C., Noel, R. J., Coats, W. S., Gomez-Foix, A. M., Alam, T., Gerard, R. D., and Newgard, C. B. (1994) Methods Cell Biol. 43, 161-189[Medline] [Order article via Infotrieve]
16. Herz, J., and Gerard, R. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2812-2816[Abstract]
17. McGarry, J. D., Stark, M. J., and Foster, D. W. (1978) J. Biol. Chem. 253, 8291-8293[Abstract]
18. Chen, S., Ogawa, A., Ohneda, M., Unger, R. H., Foster, D. W., and McGarry, J. D. (1994) Diabetes 43, 878-883[Abstract]
19. Lee, Y., Hirose, H., Ohneda, M., Johnson, J. H., McGarry, J. D., and Unger, R. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10878-10882[Abstract/Free Full Text]
20. Zhou, Y. P., and Grill, V. (1995) J. Clin. Endocrin. Metab. 80, 1584-1590[Abstract]
21. Zhang, S., and Kim, K. H. (1998) Cell. Signal. 10, 35-42[CrossRef][Medline] [Order article via Infotrieve]
22. Maechler, P., Kennedy, E. D., Pozzan, T., and Wollheim, C. B. (1997) EMBO J. 16, 3833-3841[Abstract/Free Full Text]
23. Sener, A., and Malaisse, W. J. (1991) Biochimie (Paris) 73, 1287-1290[Medline] [Order article via Infotrieve]
24. Stein, D. T., Esser, V., Stevenson, B. E., Lane, K. E., Whiteside, J. H., Daniels, M. B., Chen, S., and McGarry, J. D. (1996) J. Clin. Invest. 97, 2728-2735[Abstract/Free Full Text]
25. Dobbins, R. L., Chester, M. W., Daniels, M. B., McGarry, J. D., and Stein, D. T. (1998) Diabetes 47, 1613-1618[Abstract]
26. Koyama, K., Chen, G., Wang, M. Y., Lee, Y., Shimabukuro, M., Newgard, C. B., and Unger, R. H. (1997) Diabetes 46, 1276-1280[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.